Efficacy and safety of LixiLan, a titratable fixed-ratio combination of lixisenatide and insulin glargine, versus insulin glargine in type 2 diabetes inadequately controlled on metformin monotherapy: the LixiLan Proof-of-Concept Randomized Trial
Three RCTs [13, 33, 34] involving 186 patients provided low certainty evidence (Table 2) that L-carnitine supplementation may induce or no difference in changes in the total cholesterol levels (MD: 11.80, 95%CI: 27.13 to 3.53)
Lawyers are pursuing Ozempic, Wegovy and Mounjaro lawsuits over serious side effects, including stomach paralysis, other gastrointestinal injuries and NAION, a rare optic nerve injury linked to sudden and potentially permanent vision loss
The most common precursor is N-acetyl cysteine (NAC)
Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients